TCI Wealth Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

TCI Wealth Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$218	–	1597
2023 Q1	$218	Sell	100 -100	-50%	-$318	﹤0.01%	2325
2022 Q4	$2.41K	Hold	200	–	–	﹤0.01%	1929
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	2134
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	2180
2022 Q1	$2K	Hold	200	–	–	﹤0.01%	2011
2021 Q4	$3K	Hold	200	–	–	﹤0.01%	2018
2021 Q3	$4K	Hold	200	–	–	﹤0.01%	1794
2021 Q2	$3K	Hold	200	–	–	﹤0.01%	1816
2021 Q1	$2K	Buy	+200	New	+$1.64K	﹤0.01%	1831

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCI Wealth Advisors's ORMP Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 100 shares — an estimated $218 sold.

TCI Wealth Advisors first reported a position in ORMP in Q1 2021 and held it in 9 quarters. The position peaked at $4K in Q3 2021. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

TCI Wealth Advisors reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 100 Oramed Pharmaceuticals shares in Q2 2023, an estimated $218.
TCI Wealth Advisors first reported a position in Oramed Pharmaceuticals in Q1 2021 and held it in 9 quarters.
TCI Wealth Advisors's Oramed Pharmaceuticals position peaked at $4K in Q3 2021.
50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.